Syros Pharmaceuticals Inc... (SYRS)
NASDAQ: SYRS
· Real-Time Price · USD
0.03
0.00 (19.52%)
At close: Jun 09, 2025, 3:26 PM
Syros Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -6.4M | -23.33M | -3.71M | -64.38M | -40.14M | -36.26M | -23.79M | -4.77M | -30.25M | -34.48M | -25.15M | -23.81M | -26.03M | -22.49M | -14.23M |
Depreciation & Amortization | 325K | 331K | 334K | 279K | 612K | 650K | 638K | 770K | 724K | 726K | 747K | 773K | 765K | 749K | 731K |
Stock-Based Compensation | 1.63M | 1.8M | 2.1M | 1.72M | 3.25M | 2.81M | 2.65M | 2.9M | 2.96M | 2.69M | 2.86M | 2.88M | 2.1M | 2.45M | 2.93M |
Other Working Capital | 1.74M | -46K | -2.67M | -4.1M | 2.05M | 3.89M | -3.59M | -1.85M | -2.6M | 1.49M | -5.33M | -240K | -3.75M | -2.68M | -2.31M |
Other Non-Cash Items | -20.16M | 1.79M | -23.99M | 29.49M | 147K | 149K | -9.19M | -30.58M | -4.61M | 101K | -2.19M | 185K | 180K | 174K | 167K |
Deferred Income Tax | n/a | n/a | n/a | 8.08M | 6.06M | 2.47M | n/a | n/a | n/a | n/a | n/a | -2.46M | -1.73M | -4.59M | -7.67M |
Change in Working Capital | 3.91M | -3.92M | -2.86M | 6.26M | -1.79M | 7.79M | -7.2M | 594K | -4.6M | 4.79M | -6.29M | -526K | -3.41M | -2.75M | -3.92M |
Operating Cash Flow | -20.69M | -29.67M | -31.1M | -18.57M | -31.86M | -22.39M | -36.9M | -31.08M | -35.79M | -26.18M | -30.02M | -22.97M | -28.13M | -26.45M | -21.99M |
Capital Expenditures | n/a | n/a | n/a | -38K | n/a | 1K | -235K | -674K | -328K | -111K | -128K | -245K | -310K | -428K | -262K |
Cash Acquisitions | -125K | 96K | 29K | 1.56M | n/a | -32.92M | 25.51M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | -5.92M | -24.67M | n/a | n/a | -2.47M | -48.5M | n/a | n/a | n/a | n/a | -34.42M | -16.99M | -34.42M | n/a |
Sales Maturities Of Investments | n/a | 30.89M | n/a | n/a | 28.64M | 35.39M | 22.99M | 38.4M | 6.52M | 16M | 7.51M | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | 25.07M | 29K | 1.56M | 28.64M | 32.92M | -25.51M | 38.4M | 6.52M | 16M | 7.51M | 34.42M | -16.99M | -34.42M | n/a |
Investing Cash Flow | n/a | 25.07M | -24.64M | 1.52M | 28.64M | 32.92M | -25.75M | 37.72M | 6.19M | 15.89M | 7.38M | -245K | -17.3M | -34.84M | -262K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | -4K | -53K | -75K | -374K | -72K | -70K | -69K | -67K | -65K | -64K |
Common Stock Repurchased | 115K | n/a | n/a | n/a | n/a | n/a | n/a | 217K | -81K | n/a | n/a | 323K | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | 41K | -265K | 110K | -5K | 144K | n/a | -2.4M | 14.43M | -151K | -23K | 165K | 36K | 137K | 121K |
Financial Cash Flow | n/a | 41K | -265K | 43.38M | -5K | 140K | -53K | -10.7M | 142.06M | -222K | -93K | 96K | -67K | 72K | 70.41M |
Net Cash Flow | -20.69M | -4.56M | -56M | 27.31M | -3.22M | 10.68M | -62.7M | -4.07M | 112.47M | -10.51M | -22.73M | -23.12M | -45.49M | -61.23M | 48.16M |
Free Cash Flow | -20.69M | -29.67M | -31.1M | -18.6M | -31.86M | -22.39M | -37.14M | -31.76M | -36.12M | -26.29M | -30.14M | -23.21M | -28.44M | -26.88M | -22.25M |